The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: FGFR3 (Fibroblast Growth Factor Receptor 3)

Gene and Protein Identity Verification

The gene FGFR3 (UniProt accession P22607) encodes Fibroblast Growth Factor Receptor 3, a receptor tyrosine kinase belonging to the protein kinase superfamily, specifically the Tyr protein kinase family (nguyen2024thecomplexityand pages 4-6, ferguson2021fibroblastgrowthfactor pages 2-3). The protein is also known by the synonym JTK4 and carries the CD antigen designation CD333. FGFR3 is expressed in humans (Homo sapiens) and contains characteristic domains including FGF receptor family domains (FGF_rcpt_fam, IPR016248) and immunoglobulin-like domains (Ig-like_dom, IPR007110; Ig_I-set, IPR013098) (nguyen2024thecomplexityand pages 4-6).

Protein Structure and Domain Organization

FGFR3 exhibits a modular architecture characteristic of receptor tyrosine kinases (noeraparast2024fgfr3alterationsin pages 6-7, nguyen2024thecomplexityand pages 4-6, ferguson2021fibroblastgrowthfactor pages 2-3). The protein comprises:

1. Extracellular Region: Three immunoglobulin-like domains (D1/IgI, D2/IgII, and D3/IgIII) connected by an acidic serine-rich "acid box" between D1 and D2 (nguyen2024thecomplexityand pages 4-6, ferguson2021fibroblastgrowthfactor pages 2-3). The D2-D3 region forms the primary ligand-binding interface, while D1 contributes to receptor autoinhibition (nguyen2024thecomplexityand pages 4-6). The protein undergoes N-glycosylation at multiple sites, including predicted sites at Asn98 (D1), Asn225 (D2), and Asn261, Asn294, Asn315, and Asn328 (D3), which influence receptor stability, localization, ligand binding, and phosphorylation (nguyen2024thecomplexityand pages 6-8).

2. Transmembrane Domain: A single-pass transmembrane helix that spans the plasma membrane (ferguson2021fibroblastgrowthfactor pages 2-3, noeraparast2024fgfr3alterationsin pages 6-7).

3. Intracellular Region: A juxtamembrane region that binds signaling adaptors such as FRS2 (FGFR substrate 2) and CRK/CRKL, followed by a split tyrosine kinase domain containing conserved catalytic machinery (ferguson2021fibroblastgrowthfactor pages 2-3, ferguson2021fibroblastgrowthfactor pages 1-2).

Alternative Splicing and Isoforms

FGFR3 undergoes alternative splicing in the second half of the D3 domain, generating IIIb and IIIc isoforms with distinct ligand-binding specificities and tissue distribution patterns (nguyen2024thecomplexityand pages 4-6, ferguson2021fibroblastgrowthfactor pages 2-3). FGFR3-IIIb is predominantly expressed in epithelial tissues and preferentially binds ligands expressed in mesenchymal tissues, while FGFR3-IIIc is predominantly expressed in mesenchymal tissues and preferentially binds epithelial-derived ligands (nguyen2024thecomplexityand pages 4-6). This complementary expression pattern facilitates paracrine signaling between tissue compartments.

Catalytic Function and Enzymatic Activity

FGFR3 functions as a receptor tyrosine kinase with intrinsic ATP-dependent protein-tyrosine kinase activity (EC 2.7.10.1) (noeraparast2024fgfr3alterationsin pages 6-7, ferguson2021fibroblastgrowthfactor pages 1-2). The catalytic mechanism proceeds through the following steps:

1. Ligand Recognition: Extracellular FGF ligands bind to the D2-D3 interface of FGFR3, typically requiring heparan sulfate proteoglycans (HSPGs) as coreceptors to stabilize the ligand-receptor interaction (nguyen2024thecomplexityand pages 6-8, chen2023structuralbasisfor pages 1-2).

2. Receptor Dimerization: Ligand binding promotes formation of asymmetric FGFR3 homodimers, bringing two receptor molecules into close proximity (noeraparast2024fgfr3alterationsin pages 6-7, ferguson2021fibroblastgrowthfactor pages 2-3, ferguson2021fibroblastgrowthfactor pages 3-5). Recent structural studies have revealed that a single heparan sulfate chain enables the primary FGF-FGFR complex to recruit a secondary FGFR molecule, leading to asymmetric receptor dimerization (chen2023structuralbasisfor pages 1-2, chen2023structuralbasisfor pages 2-3).

3. Trans-autophosphorylation: Receptor dimerization enables the intracellular kinase domains to undergo trans-autophosphorylation, in which paired receptors phosphorylate tyrosine residues on one another (noeraparast2024fgfr3alterationsin pages 6-7, ferguson2021fibroblastgrowthfactor pages 2-3, ferguson2021fibroblastgrowthfactor pages 3-5). This activation creates docking sites for downstream signaling proteins.

4. Substrate Phosphorylation: The activated FGFR3 kinase phosphorylates tyrosine residues on both the receptor itself and on downstream substrate proteins, initiating signaling cascades (nguyen2024thecomplexityand pages 6-8, ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7).

Ligand Specificity

FGFR3 binds multiple FGF ligands with varying specificity depending on the splice isoform (ferguson2021fibroblastgrowthfactor pages 2-3, nguyen2024thecomplexityand pages 2-4, noeraparast2024fgfr3alterationsin pages 6-7):

• Pan-FGFR ligands: FGF1 and FGF2 bind all FGFRs, including both FGFR3 isoforms (ferguson2021fibroblastgrowthfactor pages 2-3, nguyen2024thecomplexityand pages 2-4).
• FGFR3-binding ligands: FGF4, FGF5, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, and FGF20 have been reported to bind FGFR3 (nguyen2024thecomplexityand pages 2-4, noeraparast2024fgfr3alterationsin pages 6-7).
• FGFR3c-specific endocrine ligands: FGF19, FGF21, and FGF23 bind FGFR3c (IIIc isoform) in the presence of Klotho coreceptors (αKlotho recognizes FGFR3c), enabling endocrine FGF signaling (chen2023structuralbasisfor pages 1-2, chen2023structuralbasisfor pages 2-3, ferguson2021fibroblastgrowthfactor pages 2-3).
• FGF9 subfamily: FGF9, FGF16, and FGF20 show preference for FGFR3 and FGFR4 (ferguson2021fibroblastgrowthfactor pages 2-3).

Phosphorylation Sites and Substrate Recognition

Specific tyrosine phosphorylation sites on FGFR3 have been identified. FGFR3 Tyr760 (Y760) is phosphorylated following FGF2 stimulation and recruits the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), initiating PI3K-AKT signaling (ferguson2021fibroblastgrowthfactor pages 3-5). FGFR3 also phosphorylates the downstream substrate RSK2 (p90 ribosomal S6 kinase 2) at Tyr529 and Tyr707 (ferguson2021fibroblastgrowthfactor pages 3-5). Additional phosphotyrosine docking sites recruit adaptor proteins including FRS2, STAT proteins, and PLCγ, although complete residue-by-residue mapping for FGFR3 remains less comprehensive than for FGFR1 (ferguson2021fibroblastgrowthfactor pages 2-3, ferguson2021fibroblastgrowthfactor pages 23-24).

Subcellular Localization and Functional Compartments

FGFR3 performs its primary function at the plasma membrane, where it binds extracellular FGF ligands and initiates intracellular signaling through its cytoplasmic kinase domain (szybowska2021negativeregulationof pages 2-4, nguyen2024thecomplexityand pages 4-6, noeraparast2024fgfr3alterationsin pages 6-7, ferguson2021fibroblastgrowthfactor pages 3-5). The receptor's membrane localization is determined by its transmembrane domain and regulated by trafficking mechanisms.

Following ligand-induced activation, FGFR3 undergoes endocytosis from the plasma membrane via both clathrin-mediated endocytosis (CME) and clathrin-independent endocytosis (CIE) pathways (szybowska2021negativeregulationof pages 2-4). After internalization, FGFR3 traffics to early/sorting endosomes, where the receptor is either:
- Directed toward late endosomes, multivesicular bodies, and lysosomes for degradation, which attenuates signaling (szybowska2021negativeregulationof pages 2-4, szybowska2021negativeregulationof pages 6-7)
- Recycled back to the plasma membrane, which can sustain signaling (szybowska2021negativeregulationof pages 2-4, szybowska2021negativeregulationof pages 4-6)

FGFR3 is sorted more efficiently toward lysosomal degradation compared to FGFR4, although the precise outcome depends on receptor ubiquitination, specific mutations, ligand type, and cellular context (szybowska2021negativeregulationof pages 2-4, szybowska2021negativeregulationof pages 6-7). Signaling can continue from endosomal compartments, and the signaling outputs may differ depending on whether the receptor is at the plasma membrane or in endosomes (szybowska2021negativeregulationof pages 2-4, szybowska2021negativeregulationof pages 4-6).

Some evidence suggests that FGFRs, including potentially FGFR3, can translocate to the nucleus, although the functional significance of nuclear FGFR3 is less well characterized and its role in transcriptional regulation remains to be fully elucidated (szybowska2021negativeregulationof pages 2-4, szybowska2021negativeregulationof pages 4-6). Certain activating mutations in the FGFR3 kinase domain can result in constitutive phosphorylation and retention in the endoplasmic reticulum (ER), representing an alternative localization pattern associated with pathological activation (takahashi2020mutationsofflt3 pages 6-10).

Downstream Signaling Pathways and Biochemical Mechanisms

FGFR3 activates four principal downstream signaling cascades that regulate diverse cellular processes. These pathways are summarized in the following table:

Table: This table summarizes the four principal signaling branches downstream of FGFR3, including their molecular intermediates, activation mechanisms, and major biological outputs.

1. RAS-RAF-MEK-ERK/MAPK Pathway

The MAPK/ERK pathway is a central signaling cascade activated by FGFR3 (ferguson2021fibroblastgrowthfactor pages 3-5, bogale2024therolesof pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 1-3). Following receptor autophosphorylation, the lipid-anchored adaptor FRS2α is phosphorylated and recruits SHP2 (PTPN11) and GRB2. GRB2 then recruits the guanine nucleotide exchange factor SOS, which activates RAS GTPases. Activated RAS initiates the RAF-MEK-ERK kinase cascade, ultimately activating ERK1/2, which translocate to the nucleus and phosphorylate transcription factors such as Ets-family members (ferguson2021fibroblastgrowthfactor pages 3-5, edirisinghe2024decodingfgffgfrsignaling pages 1-3). FGFR3 can also directly phosphorylate RSK2 at Tyr529 and Tyr707, linking receptor activation to ERK/RSK-dependent responses (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 23-24).

This pathway regulates proliferation, differentiation, migration, angiogenesis, and gene expression. In skeletal development, FGFR3-mediated ERK activation restrains chondrocyte proliferation and hypertrophy in the growth plate, thereby negatively regulating longitudinal bone growth (li2024roleofsignaling pages 5-7, noeraparast2024fgfr3alterationsin pages 6-7, loisay2023hypochondroplasiagainoffunctionmutation pages 10-12, wells2023identifyingfibroblastgrowth pages 11-13).

2. PI3K-AKT-mTOR Pathway

FGFR3 activates PI3K-AKT signaling through multiple mechanisms (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 1-3). Phosphorylated FRS2α recruits GRB2, which in turn recruits and phosphorylates GAB1. GAB1 then binds and activates PI3K, converting phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits and activates AKT (also known as protein kinase B), which phosphorylates numerous substrates including TSC2, mTOR complex 1 (mTORC1), and FOXO transcription factors (edirisinghe2024decodingfgffgfrsignaling pages 1-3). Additionally, FGFR3 Tyr760 phosphorylation directly recruits the p85 regulatory subunit of PI3K (ferguson2021fibroblastgrowthfactor pages 3-5).

This pathway promotes cell survival, growth, metabolism, protein synthesis, and resistance to apoptosis. FGF18-mediated PI3K/AKT signaling in chondrocytes supports proliferation, limits IL-1β-induced apoptosis, reduces oxidative stress, and restores mitochondrial function (edirisinghe2024decodingfgffgfrsignaling pages 11-12).

3. PLCγ-PKC Pathway

FGFR3 activation recruits phospholipase C gamma (PLCγ) to a C-terminal phosphotyrosine docking site through its SH2 domain (ferguson2021fibroblastgrowthfactor pages 3-5, bogale2024therolesof pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 1-3). Activated PLCγ hydrolyzes PIP2 into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 promotes release of intracellular calcium stores, while DAG and calcium together activate protein kinase C (PKC) isoforms. This pathway controls calcium-dependent cellular responses, cytoskeletal reorganization, migration, differentiation, and secretion (ferguson2021fibroblastgrowthfactor pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 1-3).

4. STAT Pathway

FGFR3 activation induces tyrosine phosphorylation of STAT1, STAT3, and STAT5 transcription factors (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 23-24, ferguson2021fibroblastgrowthfactor pages 2-3, edirisinghe2024decodingfgffgfrsignaling pages 1-3). STAT activation may involve receptor-associated complexes and can be facilitated by SRC-family kinases and JAK kinases. Phosphorylated STATs dimerize and translocate to the nucleus, where they regulate transcription of genes controlling proliferation, survival, differentiation, and inflammatory responses. In growth-plate biology, STAT signaling is associated with restraint of chondrocyte proliferation, and constitutive STAT activation contributes to FGFR3-driven oncogenic transformation (ferguson2021fibroblastgrowthfactor pages 23-24, edirisinghe2024decodingfgffgfrsignaling pages 1-3, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2).

Biological Functions and Physiological Role

Role in Skeletal Development and Bone Growth

FGFR3 functions as a negative regulator of longitudinal bone growth through its effects on growth-plate chondrocytes (li2024roleofsignaling pages 5-7, noeraparast2024fgfr3alterationsin pages 6-7, loisay2023hypochondroplasiagainoffunctionmutation pages 10-12, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21). The receptor is expressed in chondrocytes and mature osteoblasts and coordinates endochondral ossification, the process by which cartilage is transformed into bone (li2024roleofsignaling pages 5-7, zhang2024reviewofpublished pages 3-4).

FGFR3 signaling restrains chondrocyte proliferation, regulates chondrocyte hypertrophy and differentiation, and modulates the transition from cartilage to bone (li2024roleofsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 11-12, noeraparast2024fgfr3alterationsin pages 6-7). Specific FGF ligands produce distinct effects on the growth plate. FGF9 binding to FGFR3 activates ERK1/2 signaling, increases SOX9 expression, raises chondrocyte density, and promotes cartilage formation (li2024roleofsignaling pages 5-7). FGF18 signaling through FGFR3 enhances proliferation of immature chondrocytes and supports cartilage regeneration (li2024roleofsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 11-12). FGF2 treatment thickens the cartilage growth plate but inhibits angiogenesis and endochondral ossification (li2024roleofsignaling pages 5-7).

FGFR3 also influences bone formation indirectly: chondrocyte-specific deletion of FGFR3 in mice increases osteoblast numbers and bone formation, associated with increased expression of Indian hedgehog (Ihh), bone morphogenetic proteins (BMP2, BMP4, BMP7), Wnt4, and TGF-β1, and reduced Noggin expression (noeraparast2024fgfr3alterationsin pages 6-7). Activating FGFR3 mutations cause delayed formation of secondary ossification centers, reduced hypertrophic cartilage areas, decreased trabecular bone mineral density and volume, and altered cortical bone mineralization (loisay2023hypochondroplasiagainoffunctionmutation pages 10-12, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21).

Clinical Evidence from Achondroplasia

The physiological importance of FGFR3 in skeletal development is clearly demonstrated by achondroplasia, the most common form of genetic dwarfism (zhang2024reviewofpublished pages 3-4, zhang2024reviewofpublished pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). Achondroplasia is caused by gain-of-function mutations in FGFR3 that result in constitutive receptor activation (zhang2024reviewofpublished pages 3-4, zhang2024reviewofpublished pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2).

The predominant achondroplasia mutation is p.Gly380Arg (G380R), typically resulting from the c.1138G>A nucleotide change, which accounts for approximately 95-98% of achondroplasia cases (zhang2024reviewofpublished pages 3-4, zhang2024reviewofpublished pages 4-6, nita2021oncogenicfgfrfusions pages 14-15, zhang2024reviewofpublished pages 7-7). This mutation occurs in the transmembrane domain and causes ligand-independent receptor dimerization and constitutive activation (nita2021oncogenicfgfrfusions pages 14-15, zhang2024reviewofpublished pages 7-7). Additional activating mutations include p.Gly375Cys, p.Ser217Cys, p.Ser249Cys, p.Tyr278Cys, p.Ser279Cys, p.Ser344Cys, p.Ser348Cys, and p.Asn540Lys (the latter associated with the milder hypochondroplasia phenotype) (zhang2024reviewofpublished pages 3-4, zhang2024reviewofpublished pages 4-6, wells2023identifyingfibroblastgrowth pages 11-13).

These gain-of-function mutations increase tyrosine kinase activity and strengthen FGFR3's negative regulatory effects on cartilage cells, inhibiting chondrocyte proliferation and hypertrophy, disrupting bone trabecula formation and endochondral ossification, and ultimately restricting longitudinal bone growth (zhang2024reviewofpublished pages 3-4, zhang2024reviewofpublished pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). The resulting phenotype includes rhizomelic short stature (shortened proximal limbs), macrocephaly, frontal bossing, midface hypoplasia, and foramen magnum stenosis, with potential complications including sleep apnea, myelopathy, and spinal canal stenosis (zhang2024reviewofpublished pages 3-4).

Conversely, loss of FGFR3 function produces skeletal overgrowth, confirming its role as a brake on bone growth (loisay2023hypochondroplasiagainoffunctionmutation pages 20-21). The therapeutic implications are significant: FGFR inhibitors such as infigratinib can improve skeletal growth in achondroplasia mouse models, and vosoritide (a CNP analogue) has been approved for achondroplasia treatment in several countries (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2).

Role in Cancer

FGFR3 alterations are important oncogenic drivers in multiple cancer types, particularly urothelial/bladder cancer (ferguson2021fibroblastgrowthfactor pages 11-12, bogale2024therolesof pages 5-6, shan2024moleculartargetingof pages 4-5, noeraparast2024fgfr3alterationsin pages 6-7, bogale2024therolesof pages 1-3). The major classes of FGFR3 alterations in cancer include:

1. Activating Point Mutations: FGFR3 mutations occur in approximately 70% of non-muscle-invasive bladder cancers (NMIBC) and about 15% of muscle-invasive bladder cancers (MIBC) (bogale2024therolesof pages 5-6, bogale2024therolesof pages 1-3). The most frequent mutations are R248C, S249C (most common), and Y375C, which promote disulfide-linked receptor dimerization and constitutive, ligand-independent activation (bogale2024therolesof pages 5-6). Transmembrane mutations including G380R (the achondroplasia mutation) and A393E also cause ligand-independent activation (bogale2024therolesof pages 5-6). Intracellular kinase-domain mutations such as K650E and N540K enhance FGFR3 tyrosine kinase activity (ferguson2021fibroblastgrowthfactor pages 11-12). FGFR3 mutations also occur at lower frequencies in cervical cancer, glioblastoma, multiple myeloma, non-small cell lung cancer, and other cancers (noeraparast2024fgfr3alterationsin pages 6-7).

2. Gene Fusions: FGFR3 gene translocations occur in approximately 3-6% of bladder cancers, most commonly producing FGFR3-TACC3 fusion proteins (ferguson2021fibroblastgrowthfactor pages 11-12, bogale2024therolesof pages 5-6, shan2024moleculartargetingof pages 4-5). The FGFR3-TACC3 fusion produces a constitutively active FGFR3 protein that lacks regulatory C-terminal sequences and exploits TACC3-mediated oligomerization and microtubule stabilization mechanisms (ferguson2021fibroblastgrowthfactor pages 11-12, bogale2024therolesof pages 5-6). This fusion is also found in glioblastomas, cervical cancer, and lung cancer (ferguson2021fibroblastgrowthfactor pages 11-12). Less common fusions include FGFR3-BAIAP2L1, which promotes STAT1 phosphorylation (bogale2024therolesof pages 5-6).

3. Overexpression and Isoform Switching: Wild-type FGFR3 contributes to tumorigenesis through overexpression, which occurs in up to 80% of non-invasive bladder tumors and approximately 40% of muscle-invasive tumors (bogale2024therolesof pages 5-6). Isoform switching, including increased FGFR3c and reduced soluble FGFR3 variants, also contributes to oncogenesis (bogale2024therolesof pages 5-6, noeraparast2024fgfr3alterationsin pages 6-7).

4. Gene Amplification: FGFR3 amplification is the most common FGFR amplification event in urothelial/bladder cancer, though it is less frequent than point mutations (ferguson2021fibroblastgrowthfactor pages 11-12, ferguson2021fibroblastgrowthfactor pages 29-30).

In bladder cancer, activated FGFR3 signaling promotes tumor cell proliferation and survival primarily through the RAS-MAPK pathway (bogale2024therolesof pages 5-6, bogale2024therolesof pages 1-3). The relationship between FGFR3 and c-MYC is particularly important, with FGFR3 signaling stabilizing and upregulating c-MYC, which mediates downstream proliferative effects (bogale2024therolesof pages 13-14). FGFR3 alterations define a molecular subtype of bladder cancer that is potentially responsive to FGFR-targeted therapies such as erdafitinib, a pan-FGFR inhibitor approved for treatment of advanced/metastatic urothelial carcinoma with FGFR3 alterations (bogale2024therolesof pages 5-6, bogale2024therolesof pages 1-3).

Current Research Developments (2023-2024)

Recent structural biology studies have provided breakthrough insights into FGFR3 activation mechanisms. Chen et al. (2023) solved cryo-electron microscopy structures of FGF23-FGFR3c-αKlotho-heparan sulfate quaternary complexes, revealing that a single heparan sulfate chain enables asymmetric FGFR3 dimerization in which one primary receptor in the FGF23-FGFR3-αKlotho ternary complex recruits a secondary FGFR3 molecule (chen2023structuralbasisfor pages 1-2, chen2023structuralbasisfor pages 2-3). This asymmetric dimerization model overturn the previous symmetric FGFR dimerization paradigm and has important implications for understanding both physiological FGFR3 signaling and the design of FGFR-targeted therapeutics.

Multiple 2023-2024 studies have explored FGFR3 inhibitors for achondroplasia treatment. Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, has shown efficacy in improving skeletal growth and normalizing growth plate architecture in mouse models of achondroplasia and hypochondroplasia when administered early postnatally (loisay2023hypochondroplasiagainoffunctionmutation pages 10-12). Clinical development of infigratinib and other FGFR inhibitors for achondroplasia is ongoing, with the goal of improving both longitudinal bone growth and craniofacial development, including foramen magnum stenosis (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2).

In cancer therapeutics, erdafitinib remains the only FDA-approved FGFR-targeted therapy, indicated for patients with advanced/metastatic urothelial carcinoma harboring susceptible FGFR3 alterations (bogale2024therolesof pages 5-6, bogale2024therolesof pages 1-3). However, clinical trials with FGFR inhibitors have yielded mixed results due to off-target toxicities, lack of predictive biomarkers, and development of resistance mechanisms (shan2024moleculartargetingof pages 4-5, bogale2024therolesof pages 13-14). Resistance can arise through secondary FGFR3 mutations, activation of bypass signaling pathways (EGFR, ERBB2/3, MET, AKT), and other mechanisms, highlighting the need for combination therapies and more selective inhibitors (bogale2024therolesof pages 13-14).

Recent reviews have emphasized the complexity of FGFR3 biology across different cancer types. In some contexts, such as mesenchymal pancreatic cancer cells, FGFR3 may promote oncogenic behavior, while in epithelial-like cells it may suppress tumors, indicating that FGFR3's role is highly context-dependent (noeraparast2024fgfr3alterationsin pages 6-7). This complexity underscores the importance of comprehensive molecular profiling and personalized treatment approaches.

Summary

FGFR3 is a receptor tyrosine kinase that functions as a critical negative regulator of skeletal growth and endochondral bone formation through restraint of growth-plate chondrocyte proliferation and differentiation. The receptor is localized primarily at the plasma membrane, where it binds diverse FGF ligands (including FGF1/2, FGF9/16/20, FGF18, and endocrine FGFs FGF19/21/23 with Klotho) and, in cooperation with heparan sulfate coreceptors, undergoes ligand-induced dimerization and trans-autophosphorylation. Activated FGFR3 phosphorylates tyrosine residues on itself and downstream substrates, initiating four principal signaling cascades: RAS-MAPK/ERK, PI3K-AKT-mTOR, PLCγ-PKC, and STAT pathways. Following activation, FGFR3 undergoes endocytosis and traffics through endosomal compartments, where signaling can continue or be terminated through lysosomal degradation.

The physiological importance of FGFR3 is demonstrated by achondroplasia, in which gain-of-function mutations (predominantly p.Gly380Arg) cause constitutive receptor activation and skeletal dwarfism through excessive inhibition of chondrocyte proliferation. In cancer, FGFR3 alterations including activating mutations, gene fusions (especially FGFR3-TACC3), and overexpression are important oncogenic drivers, particularly in bladder cancer. Recent structural and clinical advances have improved understanding of FGFR3 activation mechanisms and therapeutic targeting strategies, though significant challenges remain in optimizing FGFR3-directed therapies for both skeletal disorders and cancer.

References

1. (nguyen2024thecomplexityand pages 4-6): Anh L. Nguyen, Caroline O. B. Facey, and Bruce M. Boman. The complexity and significance of fibroblast growth factor (fgf) signaling for fgf-targeted cancer therapies. Cancers, 17:82, Dec 2024. URL: https://doi.org/10.3390/cancers17010082, doi:10.3390/cancers17010082. This article has 21 citations.

2. (ferguson2021fibroblastgrowthfactor pages 2-3): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

3. (noeraparast2024fgfr3alterationsin pages 6-7): Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß‐Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, and Martin Pichler. Fgfr3 alterations in bladder cancer: sensitivity and resistance to targeted therapies. Cancer Communications, 44:1189-1208, Aug 2024. URL: https://doi.org/10.1002/cac2.12602, doi:10.1002/cac2.12602. This article has 51 citations.

4. (nguyen2024thecomplexityand pages 6-8): Anh L. Nguyen, Caroline O. B. Facey, and Bruce M. Boman. The complexity and significance of fibroblast growth factor (fgf) signaling for fgf-targeted cancer therapies. Cancers, 17:82, Dec 2024. URL: https://doi.org/10.3390/cancers17010082, doi:10.3390/cancers17010082. This article has 21 citations.

5. (ferguson2021fibroblastgrowthfactor pages 1-2): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

6. (chen2023structuralbasisfor pages 1-2): Lingfeng Chen, Li-li Fu, Jingchuan Sun, Zhiqiang Huang, Mingzhen Fang, Allen P. Zinkle, Xin Liu, Junliang Lu, Zixiang Pan, Yang Wang, Guang Liang, Xiaokun Li, Gaozhi Chen, and M. Mohammadi. Structural basis for fgf hormone signalling. Nature, 618:862-870, Jun 2023. URL: https://doi.org/10.1038/s41586-023-06155-9, doi:10.1038/s41586-023-06155-9. This article has 166 citations and is from a highest quality peer-reviewed journal.

7. (ferguson2021fibroblastgrowthfactor pages 3-5): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

8. (chen2023structuralbasisfor pages 2-3): Lingfeng Chen, Li-li Fu, Jingchuan Sun, Zhiqiang Huang, Mingzhen Fang, Allen P. Zinkle, Xin Liu, Junliang Lu, Zixiang Pan, Yang Wang, Guang Liang, Xiaokun Li, Gaozhi Chen, and M. Mohammadi. Structural basis for fgf hormone signalling. Nature, 618:862-870, Jun 2023. URL: https://doi.org/10.1038/s41586-023-06155-9, doi:10.1038/s41586-023-06155-9. This article has 166 citations and is from a highest quality peer-reviewed journal.

9. (ferguson2021fibroblastgrowthfactor pages 5-7): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

10. (nguyen2024thecomplexityand pages 2-4): Anh L. Nguyen, Caroline O. B. Facey, and Bruce M. Boman. The complexity and significance of fibroblast growth factor (fgf) signaling for fgf-targeted cancer therapies. Cancers, 17:82, Dec 2024. URL: https://doi.org/10.3390/cancers17010082, doi:10.3390/cancers17010082. This article has 21 citations.

11. (ferguson2021fibroblastgrowthfactor pages 23-24): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

12. (szybowska2021negativeregulationof pages 2-4): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.

13. (szybowska2021negativeregulationof pages 6-7): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.

14. (szybowska2021negativeregulationof pages 4-6): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.

15. (takahashi2020mutationsofflt3 pages 6-10): Shinichirou Takahashi. Mutations of flt3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling. Leukemia Research Reports, 13:100187, Jan 2020. URL: https://doi.org/10.1016/j.lrr.2019.100187, doi:10.1016/j.lrr.2019.100187. This article has 33 citations.

16. (bogale2024therolesof pages 3-5): Dereje E. Bogale. The roles of fgfr3 and c-myc in urothelial bladder cancer. Discover Oncology, Jul 2024. URL: https://doi.org/10.1007/s12672-024-01173-z, doi:10.1007/s12672-024-01173-z. This article has 24 citations.

17. (edirisinghe2024decodingfgffgfrsignaling pages 1-3): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

18. (li2024roleofsignaling pages 5-7): Heng-Zhen Li, Jing-lve Zhang, Dong-Liang Yuan, Wen-Qing Xie, Christoph H. Ladel, Ali Mobasheri, and Yu-Sheng Li. Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family. Military Medical Research, Jun 2024. URL: https://doi.org/10.1186/s40779-024-00544-5, doi:10.1186/s40779-024-00544-5. This article has 64 citations and is from a peer-reviewed journal.

19. (loisay2023hypochondroplasiagainoffunctionmutation pages 10-12): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 11 citations and is from a domain leading peer-reviewed journal.

20. (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 11 citations and is from a domain leading peer-reviewed journal.

21. (edirisinghe2024decodingfgffgfrsignaling pages 11-12): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

22. (wells2023identifyingfibroblastgrowth pages 11-13): Leah M. Wells, Helen C. Roberts, Frank P. Luyten, and Scott J. Roberts. Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microrna-based interaction networks. Biology, 12:1381, Oct 2023. URL: https://doi.org/10.3390/biology12111381, doi:10.3390/biology12111381. This article has 2 citations.

23. (loisay2023hypochondroplasiagainoffunctionmutation pages 20-21): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 11 citations and is from a domain leading peer-reviewed journal.

24. (zhang2024reviewofpublished pages 3-4): XinZhong Zhang, Shan Jiang, Rui Zhang, Siyi Guo, Qiqi Sheng, Kaili Wang, Yuanyuan Shan, Lin Liao, and Jianjun Dong. Review of published 467 achondroplasia patients: clinical and mutational spectrum. Orphanet Journal of Rare Diseases, Jan 2024. URL: https://doi.org/10.1186/s13023-024-03031-1, doi:10.1186/s13023-024-03031-1. This article has 22 citations and is from a peer-reviewed journal.

25. (zhang2024reviewofpublished pages 4-6): XinZhong Zhang, Shan Jiang, Rui Zhang, Siyi Guo, Qiqi Sheng, Kaili Wang, Yuanyuan Shan, Lin Liao, and Jianjun Dong. Review of published 467 achondroplasia patients: clinical and mutational spectrum. Orphanet Journal of Rare Diseases, Jan 2024. URL: https://doi.org/10.1186/s13023-024-03031-1, doi:10.1186/s13023-024-03031-1. This article has 22 citations and is from a peer-reviewed journal.

26. (nita2021oncogenicfgfrfusions pages 14-15): Alexandru Nita, Sara P. Abraham, Pavel Krejci, and Michaela Bosakova. Oncogenic fgfr fusions produce centrosome and cilia defects by ectopic signaling. Cells, 10:1445, Jun 2021. URL: https://doi.org/10.3390/cells10061445, doi:10.3390/cells10061445. This article has 14 citations.

27. (zhang2024reviewofpublished pages 7-7): XinZhong Zhang, Shan Jiang, Rui Zhang, Siyi Guo, Qiqi Sheng, Kaili Wang, Yuanyuan Shan, Lin Liao, and Jianjun Dong. Review of published 467 achondroplasia patients: clinical and mutational spectrum. Orphanet Journal of Rare Diseases, Jan 2024. URL: https://doi.org/10.1186/s13023-024-03031-1, doi:10.1186/s13023-024-03031-1. This article has 22 citations and is from a peer-reviewed journal.

28. (ferguson2021fibroblastgrowthfactor pages 11-12): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

29. (bogale2024therolesof pages 5-6): Dereje E. Bogale. The roles of fgfr3 and c-myc in urothelial bladder cancer. Discover Oncology, Jul 2024. URL: https://doi.org/10.1007/s12672-024-01173-z, doi:10.1007/s12672-024-01173-z. This article has 24 citations.

30. (shan2024moleculartargetingof pages 4-5): Khine S. Shan, Shivani Dalal, Nyein Nyein Thaw Dar, Omani McLish, Matthew Salzberg, and Brian A. Pico. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. International Journal of Molecular Sciences, 25:849, Jan 2024. URL: https://doi.org/10.3390/ijms25020849, doi:10.3390/ijms25020849. This article has 33 citations.

31. (bogale2024therolesof pages 1-3): Dereje E. Bogale. The roles of fgfr3 and c-myc in urothelial bladder cancer. Discover Oncology, Jul 2024. URL: https://doi.org/10.1007/s12672-024-01173-z, doi:10.1007/s12672-024-01173-z. This article has 24 citations.

32. (ferguson2021fibroblastgrowthfactor pages 29-30): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

33. (bogale2024therolesof pages 13-14): Dereje E. Bogale. The roles of fgfr3 and c-myc in urothelial bladder cancer. Discover Oncology, Jul 2024. URL: https://doi.org/10.1007/s12672-024-01173-z, doi:10.1007/s12672-024-01173-z. This article has 24 citations.

Artifacts

• Edison artifact artifact-00

Citations

1. nguyen2024thecomplexityand pages 4-6
2. nguyen2024thecomplexityand pages 6-8
3. ferguson2021fibroblastgrowthfactor pages 2-3
4. ferguson2021fibroblastgrowthfactor pages 3-5
5. szybowska2021negativeregulationof pages 2-4
6. edirisinghe2024decodingfgffgfrsignaling pages 1-3
7. edirisinghe2024decodingfgffgfrsignaling pages 11-12
8. li2024roleofsignaling pages 5-7
9. zhang2024reviewofpublished pages 3-4
10. loisay2023hypochondroplasiagainoffunctionmutation pages 20-21
11. loisay2023hypochondroplasiagainoffunctionmutation pages 1-2
12. bogale2024therolesof pages 5-6
13. ferguson2021fibroblastgrowthfactor pages 11-12
14. bogale2024therolesof pages 13-14
15. loisay2023hypochondroplasiagainoffunctionmutation pages 10-12
16. ferguson2021fibroblastgrowthfactor pages 1-2
17. chen2023structuralbasisfor pages 1-2
18. chen2023structuralbasisfor pages 2-3
19. ferguson2021fibroblastgrowthfactor pages 5-7
20. nguyen2024thecomplexityand pages 2-4
21. ferguson2021fibroblastgrowthfactor pages 23-24
22. szybowska2021negativeregulationof pages 6-7
23. szybowska2021negativeregulationof pages 4-6
24. bogale2024therolesof pages 3-5
25. wells2023identifyingfibroblastgrowth pages 11-13
26. zhang2024reviewofpublished pages 4-6
27. nita2021oncogenicfgfrfusions pages 14-15
28. zhang2024reviewofpublished pages 7-7
29. shan2024moleculartargetingof pages 4-5
30. bogale2024therolesof pages 1-3
31. ferguson2021fibroblastgrowthfactor pages 29-30
32. https://doi.org/10.3390/cancers17010082,
33. https://doi.org/10.3390/cells10051201,
34. https://doi.org/10.1002/cac2.12602,
35. https://doi.org/10.1038/s41586-023-06155-9,
36. https://doi.org/10.3390/cells10061342,
37. https://doi.org/10.1016/j.lrr.2019.100187,
38. https://doi.org/10.1007/s12672-024-01173-z,
39. https://doi.org/10.3390/biom14121622,
40. https://doi.org/10.1186/s40779-024-00544-5,
41. https://doi.org/10.1172/jci.insight.168796,
42. https://doi.org/10.3390/biology12111381,
43. https://doi.org/10.1186/s13023-024-03031-1,
44. https://doi.org/10.3390/cells10061445,
45. https://doi.org/10.3390/ijms25020849,